Experimental cancer drug KD033 tested in early trial – but study halted
Disease control
Terminated
This early-phase study tested an experimental drug called KD033 (SAR445710) in 45 adults with advanced or metastatic solid tumors. The main goal was to check safety and find the right dose, while also looking for any anti-cancer effects. The trial was terminated, so final results…
Phase: PHASE1 • Sponsor: Kadmon, a Sanofi Company • Aim: Disease control
Last updated Jun 26, 2026 18:02 UTC